Soleno Therapeutics (SLNO) officer reports RSU-related share withholding

Rhea-AI Filing Summary

Soleno Therapeutics insider reports routine tax withholding transaction. A senior officer of Soleno Therapeutics Inc. reported an automatic disposition of company stock related to vested restricted stock units on December 15, 2025.

The filing shows that 904 shares of common stock were withheld by the company at a price of $49.95 per share to cover the officer's tax obligations when RSUs vested. After this transaction, the officer beneficially owned 27,239 shares of Soleno Therapeutics common stock. The reported RSUs each represent a contingent right to receive one share of common stock, subject to vesting conditions.

The reporting person serves as SVP Global Clinical Operations and Patient Advocacy, and this filing reflects a standard administrative equity compensation event rather than an open-market trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yen Kristen

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		F(1)		904	D	$49.95	27,239(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") which vested on December 15, 2025.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Remarks:

Officer title: SVP Global Clinical Operations and Patient Advocacy

	/s/ Anish Bhatnagar, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soleno Therapeutics (SLNO) report in this Form 4?

The Form 4 reports that a Soleno Therapeutics officer had 904 shares of common stock withheld on December 15, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units.

At what price were the Soleno Therapeutics (SLNO) shares withheld for taxes?

The filing states that the 904 withheld shares of Soleno Therapeutics common stock were valued at $49.95 per share for tax withholding purposes.

How many Soleno Therapeutics (SLNO) shares does the reporting officer own after this transaction?

Following the reported tax withholding transaction, the officer beneficially owned 27,239 shares of Soleno Therapeutics common stock in direct ownership.

What do the Soleno Therapeutics restricted stock units (RSUs) represent in this Form 4?

The filing explains that certain securities are RSUs, with each RSU representing a contingent right to receive one share of common stock, subject to applicable vesting schedules and conditions.

What is the role of the reporting person at Soleno Therapeutics (SLNO)?

The reporting person is identified as an officer of Soleno Therapeutics with the title SVP Global Clinical Operations and Patient Advocacy.

Was this Soleno Therapeutics (SLNO) Form 4 filed for one or multiple reporting persons?

The document indicates that the Form 4 was filed by one reporting person, not by a group or joint filers.